|
CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE ESSAIS TESTANT LE ROLE DE L’ADDITION D’AUTRES AGENTS AU CISPLATINE
|
|
référence
|
chimiothérapie
|
n
|
(stIV)
|
% RO
|
p
|
SM
|
p
|
Georgoulias,
2001 (1)
|
I. CDDP (80 mg/m²)+docetaxel (100 mg/m²)
|
205
|
(129)
|
35
|
NS
|
10 m
|
NS
|
II. Gemci + docetaxel (100 mg/m²)
|
201
|
(130)
|
33
|
9,5 m
|
Sculier,
2002 (2)
|
I.CDDP (50) + Carbo (200) + Ifo
|
94
|
tous
|
23
|
NS
|
24
s
|
NS
|
II.CDDP(50) + Carbo (200) +Gemci
|
92
|
29
|
34
s
|
III.Ifo + gemcitabine
|
94
|
25
|
30
s
|
Kosmidis,
2002 (3)
|
I. Paclitaxel (200 mg/m²) + Carbo (AUC 6)
|
252
|
(158)
|
28
|
0,12
|
10,4 m
|
0,32
|
II. Paclitaxel (200 mg/m²) + gemcitabine
|
257
|
(148)
|
35
|
9,8 m
|
Greco,
2002 (4)
|
I. CBDCA
(AUC 5)+paclitaxel (200)+ gemci
|
71
|
(51)
|
37
|
NS
|
9,2 m
|
NS
|
II. CBDCA
(AUC 6)+paclitaxel (200)+ VNR
|
65
|
(51)
|
45
|
8,6 m
|
III.
paclitaxel (200)+ gemci
|
64
|
(53)
|
32
|
8,7 m
|
IV. Gemci
+ VNR
|
67
|
(49)
|
33
|
10,7 m
|
Chen,
2002 (5)
|
I. Carboplatine
(AUC 7) + paclitaxel (175)
|
45
|
|
40
|
|
14,1 m
|
|
II.
paclitaxel (175)+ gemci
|
45
|
|
40
|
12,6 m
|
Gebbia,
2003 (6)
|
I. CDDP + gemcitabine
|
138
|
(73)
|
34
|
0.007
|
8,2
m
|
NS
|
II. CDDP + vinorelbine
|
140
|
(75)
|
44
|
9,0
m
|
III. Ifo + gemcitabine puis CDDP + VNR
|
60
|
(33)
|
19
|
|
IV. CDDP + VNR puis Ifo + gemcitabine
|
60
|
(31)
|
31
|
|
Gridelli,
2003 (7)
|
I. CDDP (80) + VNR
|
126
|
80%
|
30
|
NS
|
38
s
|
0,08
|
II. CDDP (80) + gemcitabine
|
126
|
81%
|
III. VNR + gemcitabine
|
251
|
80%
|
25
|
32
s
|
Alberola,
2003 (8)
|
I. CDDP (100) + gemcitabine
|
182
|
77 %
|
42
|
S
|
9,3
m
|
NS
|
II. CDDP (100) + gemcitabine + VNR
|
188
|
79 %
|
41
|
8,2
m
|
III. gemci + VNR x 3 puis Ifo + VNR x 3
|
187
|
81 %
|
27
|
8,1 m
|
Smit,
2003(9)
|
I. paclitaxel (175) + CDDP (80)
|
159
|
(130)
|
32
|
NS
|
8,1 m
|
NS
|
II. CDDP (80) + gemci
|
160
|
(126)
|
37
|
8,9 m
|
III. paclitaxel (175) + gemci
|
161
|
(136)
|
28
|
6,7 m
|
Wachters,
2004 (10)
|
I. CDDP + gemcitabine
|
119
|
57%
|
46%
|
NS
|
43
s
|
0,14
|
|
121
|
57%
|
36%
|
36
s
|
Yamamoto,
2004 (11)
|
|
51
|
(40)
|
37
%
|
NS
|
50
s
|
NS
|
|
57
|
(43)
|
32
%
|
46
s
|
Laack,
2004 (12)
|
|
144
|
(126)
|
28 %
|
0,004
|
32 s
|
0,73
|
|
143
|
(125)
|
13 %
|
36 s
|
Stathopoulos,
2004 (13)
|
|
175
|
47%
|
43 %
|
NS
|
10 m
|
NS
|
|
185
|
49%
|
46 %
|
11 m
|
Lilenbaum,
2005 (14)
|
|
82
|
82%
|
14,6 %
|
|
7,8 m
|
|
|
83
|
81%
|
16,9%
|
8,6m
|
Chen,
2005(15)
|
|
43
|
77%
|
23 %
|
0,02
|
9,5 m
|
NS
|
|
43
|
81%
|
46 %
|
13,1 m
|
Pujol,
2005 (16)
|
|
155
|
79 %
|
31 %
|
NS
|
11,1 m
|
NS
|
|
156
|
86 %
|
36 %
|
9,6 m
|
Georgoulias,
2005 (17)
|
|
204
|
64%
|
39 %
|
0,053
|
8,6 m
|
NS
|
|
209
|
62%
|
30 %
|
9,0 m
|
Tan,
2005 (18)
|
|
157
|
80%
|
28 %
|
0,15
|
11,5 m
|
0,01
|
|
159
|
90%
|
21 %
|
8,5 m
|
Kosmidis, 2007 (19)
|
|
47
|
64%
|
4%
|
0,14
|
4,8 m
|
0,49
|
|
43
|
74%
|
14%
|
6,7 m
|
Références
(1) Georgoulias
V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, et al. Platinum-based and
non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a
randomised multicentre trial. Lancet 2001 May 12;357(9267):1478-84.
(2) Sculier
JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, et al. A three-arm phase III randomised
trial comparing combinations of platinum derivatives, ifosfamide and/or
gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002
Jun;13(6):874-82.
(3)
Kosmidis P, Mylonakis N,
Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, et al. Paclitaxel plus
carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung
cancer: a phase III randomized trial. J Clin Oncol 2002 Sep 1;20(17):3578-85.
(4)
Greco FA, Gray JR, Jr., Thompson DS,
Burris HA, III, Erland JB, Barton JH, Jr., et al. Prospective randomized study
of four novel chemotherapy regimens in patients with advanced nonsmall cell
lung carcinoma: a minnie pearl cancer research network trial. Cancer 2002 Sep
15;95(6):1279-85.
(5)
Chen YM, Perng RP, Lee YC, Shih JF, Lee
CS, Tsai CM, et al. Paclitaxel plus carboplatin, compared with paclitaxel plus
gemcitabine, shows similar efficacy while more cost-effective: a randomized
phase II study of combination chemotherapy against inoperable non-small-cell
lung cancer previously untreated. Ann Oncol 2002 Jan;13(1):108-15.
(6)
Gebbia V, Galetta D, Caruso M,
Verderame F, Pezzella G, Valdesi M, et al. Gemcitabine and cisplatin versus
vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine
and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and
gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective
randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung
Cancer 2003 Feb;39(2):179-89.
(7)
Gridelli C, Gallo C, Shepherd FA,
Illiano A, Piantedosi F, Robbiati SF, et al. Gemcitabine plus vinorelbine
compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for
advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN
Investigators and the National Cancer Institute of Canada Clinical Trials
Group. J Clin Oncol 2003 Aug 15;21(16):3025-34.
(8)
Alberola V, Camps C, Provencio M, Isla
D, Rosell R, Vadell C, et al. Cisplatin plus gemcitabine versus a
cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell
lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin
Oncol 2003 Sep 1;21(17):3207-13.
(9)
Smit EF, van Meerbeeck JP, Lianes P,
Debruyne C, Legrand C, Schramel F, et al. Three-arm randomized study of two
cisplatin-based regimens and paclitaxel plus gemcitabine in advanced
non-small-cell lung cancer: a phase III trial of the European Organization for
Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol
2003 Nov 1;21(21):3909-17.
(10)
Wachters FM, Van Putten
JW, Kramer H, Erjavec Z, Eppinga P, Strijbos JH, et al. First-line gemcitabine
with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase
III trial. Br J Cancer 2003 Oct 6;89(7):1192-9.
(11)
Yamamoto N, Fukuoka M,
Negoro SI, Nakagawa K, Saito H, Matsui K, et al. Randomised phase II study of
docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung
cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br J Cancer
2004 Jan 12;90(1):87-92.
(12)
Laack E, Dickgreber N, Muller T, Knuth
A, Benk J, Lorenz C, et al. Randomized phase III study of gemcitabine and
vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of
advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer
Study Group. J Clin Oncol 2004 Jun 15;22(12):2348-56.
(13)
Stathopoulos GP, Veslemes
M, Georgatou N, Antoniou D, Giamboudakis P, Katis K, et al. Front-line
paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced
non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 2004 Jul;15(7):1048-55.
(14)
Lilenbaum RC, Chen CS,
Chidiac T, Schwarzenberger PO, Thant M, Versola M, et al. Phase II randomized trial of
vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced
non-small-cell lung cancer. Ann Oncol 2005 Jan;16(1):97-101.
(15)
Chen YM, Perng RP, Shih JF, Tsai CM,
Whang-Peng J. A randomized phase II study of vinorelbine plus gemcitabine
with/without cisplatin against inoperable non-small-cell lung cancer previously
untreated. Lung Cancer 2005 Mar;47(3):373-80.
(16) Pujol
JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morere JF, et al. Gemcitabine-docetaxel versus
cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a
phase III study addressing the case for cisplatin. Ann Oncol 2005
Apr;16(4):602-10.
(17)
Georgoulias V, Ardavanis
A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al.
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell
lung cancer: a phase III randomized trial. J Clin Oncol 2005 May
1;23(13):2937-45.
(18)
Tan EH, Szczesna A, Krzakowski M, Macha
HN, Gatzemeier U, Mattson K, et al. Randomized study of
vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with
advanced non-small cell lung cancer. Lung Cancer 2005 Aug;49(2):233-40.
(19) Kosmidis PA, Dimopoulos M,
Syrigos K, Nicolaides C, Aravantinos G, Boukovinas I, et al. Gemcitabine versus gemcitabine-carboplatin for
patients with advanced non-small cell lung cancer and a performance status of 2
: a prospective randomised phase II study of the Hellenic Cooperative Oncology
Group. J Thorac Oncol 2007;2:135-40.
|